Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors

被引：0
|
作者：
Gomez Puerto, D. A. [1 ]
Rossi, A. [2 ]
Hernando Calvo, A. [1 ]
Ucha Hermida, J. M. [1 ]
Gomez, M. [3 ]
Matito, J. [3 ]
Vila-Casadesus, M. [3 ]
Morchon Araujo, D. [4 ]
Dienstmann, R. [5 ]
Galceran, J. C. [1 ]
Illescas, D. G. [1 ]
Macarulla Mercade, T. [1 ]
Garralda, E. [1 ]
Saura Manich, C. [1 ]
Elez Fernandez, M. E. [1 ]
Felip, E. [1 ]
Tabernero, J. [1 ]
Vivancos, A. [3 ]
机构：
[1] Vall dHebron Inst Oncol, Med Oncol Dept, Barcelona, Spain
[2] Azienda Osped Univ Integrata Verona, Med Oncol Dept, Verona, Italy
[3] VHIO Valle Hebron Inst Oncol, Genom Dept, Barcelona, Spain
[4] Univ Hosp Salamanca, Med Oncol Dept, Salamanca, Spain
[5] Vall dHebron Inst Oncol, Oncol Data Sci Dept, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.135
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
127P
引用
收藏
页码：S265 / S266
页数：2
相关论文
共 50 条
  • [21] Next generation sequencing (NGS) in older adults with breast cancer using tissue-based and circulating tumor DNA (ctDNA) assays
    Clifton, Katherine K.
    Luo, Jingqin
    Tao, Yu
    Saam, Jennifer
    Rich, Thereasa
    Rearden, Timothy
    Roshal, Anna
    Frith, Ashley
    Rigden, Caron
    Ademuyiwa, Foluso
    Weilbaecher, Katherine
    Aya, Leonel Hernandez
    Peterson, Lindsay
    Bagegni, Nusayba
    Suresh, Rama
    Bose, Ron
    Wildes, Tanya
    Opyrchal, Mateusz
    Ma, Cynthia
    CANCER RESEARCH, 2021, 81 (04)
  • [22] Clinical Impact of Next-Generation Sequencing (NGS) in Blood Liquid Biopsies for Treatment Decisions in Advanced NSCLC
    Garcia Pardo, M.
    Martinez Delfrade, I.
    Aparicio Salcedo, I.
    Arregui Valles, M.
    Alva Bianchi, M.
    Tirado Anula, V.
    Alvarez, R.
    Calles Blanco, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S840 - S841
  • [23] Circulating tumour (ct) DNA next generation sequencing (NGS) in UK advanced non-small cell lung cancer (aNSCLC) patients (pts)
    Cui, W.
    Milner-Watts, C.
    Lyons, H.
    Yousaf, N.
    Minchom, A. R.
    Bhosle, J.
    Davidson, M.
    Scott, S.
    Faull, I.
    Nagy, R. J.
    O'Brien, M. E. R.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S787 - S788
  • [24] Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors
    Jeffrey C. Thompson
    Dylan G. Scholes
    Erica L. Carpenter
    Charu Aggarwal
    British Journal of Cancer, 2023, 129 : 1893 - 1902
  • [25] COMPREHENSIVE GENOMIC TESTING IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A COST-EFFECTIVENESS ANALYSIS OF PLASMA-BASED CIRCULATING TUMOR DNA (CTDNA) NEXT-GENERATION SEQUENCING (NGS) TO INFORM FIRST-LINE TREATMENT DECISIONS
    Lopes, G.
    Liu, E.
    Raymond, V
    Scott, J.
    Ho, V
    Gandara, D.
    VALUE IN HEALTH, 2020, 23 : S326 - S326
  • [26] Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors
    Thompson, Jeffrey C.
    Scholes, Dylan G.
    Carpenter, Erica L.
    Aggarwal, Charu
    BRITISH JOURNAL OF CANCER, 2023, 129 (12) : 1893 - 1902
  • [27] Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications
    Hahn, Andrew W.
    Gill, David M.
    Maughan, Benjamin
    Agarwal, Archana
    Arjyal, Lubina
    Gupta, Sumati
    Streeter, Jessica
    Bailey, Erin
    Pal, Sumanta K.
    Agarwal, Neeraj
    ONCOTARGET, 2017, 8 (20) : 33614 - 33620
  • [28] Targeted next-generation sequencing (NGS) of 105 cancer-related genes in circulating tumor DNA (ctDNA) from patients with advanced cancers treated with immune checkpoint inhibitors (iCPI).
    Call, S. Greg
    Huang, Helen J.
    Rodon, Jordi
    Karp, Daniel D.
    Tsimberidou, Apostolia M.
    Naing, Aung
    Janku, Filip
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (02)
  • [29] Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)
    Moovendhan, Meivelu
    ORAL ONCOLOGY, 2024, 157
  • [30] Validation for clinical use of NGS-based assay to detect circulating tumor DNA (ctDNA) in patients (pts) with various types of cancer
    Fedyanin, M.
    Boyarskikh, U.
    Kechin, A.
    Polyanskaya, E.
    Aliev, V.
    Polyakov, A.
    Kudashkin, N.
    Arzumanyan, A.
    Gordeeva, O. O.
    Bagrova, S.
    Tikhonovskaya, M.
    Trigolosov, A.
    Denchik, D.
    Nikulin, M.
    Nered, S.
    Moroz, E.
    Chekini, A.
    Filipenko, M.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S279 - S279
12345